The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of FOLFIRI with low-dose irinotecan plus ramucirumab as second-line treatment in Japanese patients with metastatic colorectal cancer (RINDO study).
 
Masashi Hattori
No Relationships to Disclose
 
Norifumi Hattori
No Relationships to Disclose
 
Goro Nakayama
No Relationships to Disclose
 
Shinichi Umeda
No Relationships to Disclose
 
Takayoshi Kishida
No Relationships to Disclose
 
Yoshihisa Kawase
No Relationships to Disclose
 
Kazuhiro Ezaka
No Relationships to Disclose
 
Masayuki Tsutsuyama
No Relationships to Disclose
 
Mitsuru Sakai
No Relationships to Disclose
 
Takeshi Ito
No Relationships to Disclose
 
Yutaka Yanbe
No Relationships to Disclose
 
Mitsuro Kanda
No Relationships to Disclose
 
Chie Tanaka
No Relationships to Disclose
 
Kenta Murotani
No Relationships to Disclose
 
Masahiko Ando
No Relationships to Disclose
 
Yasuhiro Kodera
Stock and Other Ownership Interests - Abbvie
Honoraria - Bristol Myers Squibb; Chugai Pharma; Daiichi Sankyo; Edwards Lifesciences; Lilly Japan; Miyarisan Pharmaceutical; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Yakult Honsha
Consulting or Advisory Role - Daii Sankyo
Research Funding - abbott Japan (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); EA Pharma (Inst); Kaken Pharmaceutical (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)